Association with trastuzumab (Herceptin®) for the targeting of human epidermal growth factor receptor-2 (HER2/neu), a tyrosine kinase receptor that is overexpressed in more malignant forms of metastatic breast or ovarian cancers, represents another consequent part of 227Th investigations. Here, ERBB2 is linked to ovarian carcinoma.